Preclinical safety testing of monoclonal antibodies: the significance of species relevance

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1× · see citing works

Monoclonal antibody successes in the clinic

Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 736 · see citing works

Loss of Siglec expression on T lymphocytes during human evolution

Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204 · see citing works

Scientific and regulatory considerations on the immunogenicity of biologics

Shankar, G., Shores, E. W., Wagner, C. L., & Mire‐Sluis, A. R. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.04.001 · Cited by 175 · see citing works

Monoclonal antibodies market

Reichert, J. M., & Pavlou, A. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1386 · Cited by 122 · see citing works

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

Mould, D. R., Davis, C. B., Minthorn, E. A., Kwok, D. C., Elliott, M. J., Luggen, M. E., & Totoritis, M. C. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70032-9 · Cited by 83 · see citing works

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

Clarke, J. B., Leach, W., Pippig, S. D., Joshi, A., Wu, B. M., House, R. V., & Beyer, J. C. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.06.007 · Cited by 77 · see citing works

Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies

Bugelskil, P. J., Herzykl, D. J., Rehm, S., Harmsen, A. G., Gore, E., Williams, D. M., Maleeff, B. E., Badger, A. M., Truneh, A., O'Brien, S., et al. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700678815783 · Cited by 75 · see citing works

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

Kon, O. M., Sihra, B. S., Loh, L., Barkans, J. R., Compton, C. H., Barnes, N., Larché, M., & Kay, A. B. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00064101 · Cited by 67 · see citing works

Anti-infective monoclonal antibodies: perils and promise of development

Reichert, J. M., & Dewitz, M. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1987 · Cited by 58 · see citing works

Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice

Herzyk, D. J., Gore, E. R., Polsky, R., Nadwodny, K. L., Maier, C. C., Liu, S., Hart, T. K., Harmsen, A. G., & Bugelski, P. J. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1032-1043.2001 · Cited by 47 · see citing works

Comparative Pharmacodynamics of Keliximab and Clenoliximab in Transgenic Mice Bearing Human CD4

Sharma, A., Davis, C. B., Tobia, L. A. P., Kwok, D. C., Tucci, M. G., Gore, E. R., Herzyk, D. J., & Hart, T. K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39200-6 · Cited by 41 · see citing works

Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.

Yocum, D. E., Solinger, A. M., Tesser, J., Gluck, O. S., Cornett, M., O’Sullivan, F. X., Nordensson, K., Dallaire, B. K., Cd, S., & Lipani, J. A. (1998) · PubMed · Cited by 30 · see citing works

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

Wu, B. M., Joshi, A., Ren, S., & Ng, C. M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20475 · Cited by 28 · see citing works

Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals

Snodin, D. J., & Ryle, P. R. (2006) · BioDrugs · doi:10.2165/00063030-200620010-00003 · Cited by 26 · see citing works

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4‐specific monoclonal antibodies: CD4+ T‐cell depletion is not required

Podolin, P. L., Webb, E. F., Reddy, M. P., Truneh, A., & Griswold, D. E. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00946.x · Cited by 21 · see citing works

Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective

Schwieterman, W. D. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.011 · Cited by 20 · see citing works

Exploiting directed evolution for the discovery of biologicals.

Douthwaite, J. A., & Jermutus, L. (2006) · PubMed · Cited by 7 · see citing works

The safety and side effects of monoclonal antibodies

Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,151 · see citing works

Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies

Pentšuk, N., & van der Laan, J. W. (2009) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20201 · Cited by 287 · see citing works

Developmental and reproductive toxicology studies in nonhuman primates

Chellman, G. J., Bussiere, J. L., Makori, N., Martin, P. L., Ooshima, Y., & Weinbauer, G. F. (2009) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20216 · Cited by 160 · see citing works

Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs).

Burden, N., Chapman, K. L., Sewell, F. R., & Robinson, V. (2015) · PubMed Central · Cited by 156 · see citing works

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149 · see citing works

Immunotoxicity of monoclonal antibodies

Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140 · see citing works

Antibody Drug Conjugates: Nonclinical Safety Considerations

Hinrichs, M. J., & Dixit, R. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9790-0 · Cited by 115 · see citing works

Capture, isolation and release of cancer cells with aptamer-functionalized glass bead array

Wan, Y., Liu, Y., Allen, P. B., Asghar, W., Mahmood, M. A. I., Tan, J., Duhon, H., Kim, Y. T., Ellington, A. D., & Iqbal, S. M. (2012) · Lab on a Chip · doi:10.1039/c2lc21251j · Cited by 111 · see citing works

Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment

Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102 · see citing works

Drug Development of Therapeutic Monoclonal Antibodies

Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 101 · see citing works

Preclinical development of monoclonal antibodies

Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 99 · see citing works

Opportunities for the replacement of animals in the study of nausea and vomiting

Holmes, A., Rudd, J. A., Tattersall, F., Aziz, Q., & Andrews, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00176.x · Cited by 86 · see citing works

Developmental toxicity testing of monoclonal antibodies: An enhanced pre- and postnatal study design option

Stewart, J. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.04.002 · Cited by 79 · see citing works

Induction of Progressive Demyelinating Autoimmune Encephalomyelitis in Common Marmoset Monkeys Using MOG34-56Peptide in Incomplete Freund Adjuvant

Jagessar, S. A., Kap, Y. S., Heijmans, N., van Driel, N., van Straalen, L., Bajramovic, J. J., Brok, H., Blezer, E. L. A., Bauer, J., Laman, J. D., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d5d053 · Cited by 77 · see citing works

Clinical immunotoxicity of therapeutic proteins

Descotes, J., & Gouraud, A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802525496 · Cited by 76 · see citing works

The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations

Jarvis, P., Srivastav, S., Vogelwedde, E., Stewart, J., Mitchard, T. L., & Weinbauer, G. F. (2010) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20234 · Cited by 70 · see citing works

Chimpanzees in Biomedical and Behavioral Research

Institute of Medicine and National Research Council (2011) · National Academies Press eBooks · doi:10.17226/13257 · Cited by 128 · see citing works

The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates

Chapman, K. L., Andrews, L., Bajramovic, J. J., Baldrick, P., Black, L. E., Bowman, C., Buckley, L. A., Coney, L., Couch, J. A., Dempster, A. M., et al. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2011.10.016 · Cited by 67 · see citing works

Validity of animal models of type 1 diabetes, and strategies to enhance their utility in translational research

Graham, M. L., & Schuurman, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.054 · Cited by 64 · see citing works

Working in partnership to advance the 3Rs in toxicity testing

Holmes, A. M., Creton, S. K., & Chapman, K. L. (2009) · Toxicology · doi:10.1016/j.tox.2009.11.006 · Cited by 62 · see citing works

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

Lynch, C. M., Hart, B. W., & Grewal, I. S. (2009) · mAbs · doi:10.4161/mabs.1.1.7377 · Cited by 59 · see citing works

Functional assessment of sexual maturity in male macaques (Macaca fascicularis)

Luetjens, C. M., & Weinbauer, G. F. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.05.003 · Cited by 59 · see citing works

Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator

Auyeung-Kim, D. J., Devalaraja, M. N., Migone, T., Cai, W., & Chellman, G. J. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.07.002 · Cited by 58 · see citing works

Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals

Vargas, H. M., Amouzadeh, H. R., & Engwall, M. J. A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.745851 · Cited by 55 · see citing works

Overview of known non-human primate pathogens with potential to affect colonies used for toxicity testing

Sasseville, V. G., & Mansfield, K. G. (2009) · Journal of Immunotoxicology · doi:10.3109/15476910903213521 · Cited by 54 · see citing works

Translational strategies for development of monoclonal antibodies from discovery to the clinic

Tabrizi, M. A., Bornstein, G. G., Klakamp, S. L., Drake, A. W., Knight, R., & Roskos, L. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.008 · Cited by 53 · see citing works

Impact of Infections and Normal Flora in Nonhuman Primates on Drug Development

Sasseville, V. G., & DITERS, R. W. (2008) · ILAR Journal · doi:10.1093/ilar.49.2.179 · Cited by 50 · see citing works

Considerations Regarding Nonhuman Primate Use in Safety Assessment of Biopharmaceuticals

Buckley, L. A., Chapman, K. L., Burns‐Naas, L. A., Todd, M. D., Martin, P. L., & Lansita, J. A. (2011) · International Journal of Toxicology · doi:10.1177/1091581811415875 · Cited by 43 · see citing works

The future of non-human primate use in mAb development

Chapman, K. L., Pullen, N., Andrews, L., & Ragan, I. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.002 · Cited by 43 · see citing works

Protein drug delivery: current dosage form profile and formulation strategies

Geraldes, D. C., Beraldo-de-Araújo, V. L., Pardo, B. O. P., Pessoa, A., Stephano, M. A., & Nascimento, L. D. O. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1669043 · Cited by 40 · see citing works

Polymorphisms and Interspecies Differences of the Activating and Inhibitory FcγRII of Macaca nemestrina Influence the Binding of Human IgG Subclasses

Trist, H. M., Tan, P. S., Wines, B. D., Ramsland, P. A., Orlowski, E., Stubbs, J., Gardiner, E. E., Pietersz, G. A., Kent, S. J., Stratov, I., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301554 · Cited by 39 · see citing works

Preclinical Development of Nononcogenic Drugs (Small and Large Molecules)

Colerangle, J. B. (2017) · A Comprehensive Guide to Toxicology in Nonclinical Drug Development · doi:10.1016/b978-0-12-803620-4.00025-6 · Cited by 37 · see citing works

A methodological review of induced animal models of autoimmune diseases

Yu, X., & Petersen, F. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.03.001 · Cited by 38 · see citing works

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges

Chapman, K. L., Adjei, A., Baldrick, P., da Silva, A., Smet, K. D., DiCicco, R. L., Hong, S. S., Jones, D., Leach, M. W., McBlane, J. W., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1145331 · Cited by 36 · see citing works

Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis

Vierboom, M., Breedveld, E., Kondova, I. I., & Hart, B. A. ‘. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3172 · Cited by 36 · see citing works

The enhanced pre‐ and postnatal study for nonhuman primates: Update and perspectives

Weinbauer, G. F., Fuchs, A., Niehaus, M., & Luetjens, C. M. (2011) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20220 · Cited by 36 · see citing works

A snapshot of biologic drug development

Andrews, L., Ralston, S. L., Blomme, E. A. G., & Barnhart, K. F. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115603594 · Cited by 36 · see citing works

Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor

Ueda, O., Tateishi, H., Higuchi, Y., Fujii, E., Kato, A., Kawase, Y., Wada, N. A., Tachibe, T., Kakefuda, M., Goto, C., et al. (2013) · Scientific Reports · doi:10.1038/srep01196 · Cited by 35 · see citing works

Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies

Tabrizi, M. A., Funelas, C. B., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9220-2 · Cited by 35 · see citing works

Typical pitfalls in applications for marketing authorization of biotechnological products in Europe

Schneider, C. K., & Schäffner-Dallmann, G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2728 · Cited by 35 · see citing works

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies

Tosi, D., Laghzali, Y., Vinches, M., Alexandre, M., Homicsko, K., Fasolo, A., Del Conte, G., Durigova, A., Hayaoui, N., Gourgou, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1082 · Cited by 33 · see citing works

Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors

Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R., & Chiu, M. L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.006 · Cited by 33 · see citing works

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

Sewell, F. R., Chapman, K. L., Couch, J. A., Dempster, M., Heidel, S. M., Loberg, L. I., Maier, C. C., MacLachlan, T. K., Todd, M. D., & van der Laan, J. W. (2017) · mAbs · doi:10.1080/19420862.2017.1324376 · Cited by 31 · see citing works

An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model

Ubah, O. C., Steven, J., Porter, A. J., & Barelle, C. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00526 · Cited by 28 · see citing works

Biologics in organ transplantation

Page, E. K., Dar, W. A., & Knechtle, S. J. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01456.x · Cited by 29 · see citing works

Effects of social housing of sexually mature male cynomolgus monkeys during general and reproductive toxicity evaluation

Niehoff, M. O., Bergmann, M., & Weinbauer, G. F. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.09.007 · Cited by 28 · see citing works

Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop

Buckley, L. A., Benson, K. A., Davis-Bruno, K. L., Dempster, M., Finch, G. L., Harlow, P., Haggerty, H. G., Hart, T. K., Kinter, L. B., Leighton, J. K., et al. (2008) · International Journal of Toxicology · doi:10.1080/10915810802367016 · Cited by 28 · see citing works

Advantages ofPapio anubisfor preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28

Poirier, N., Mary, C., Bas‐Bernardet, S. L., Daguin, V., Belarif, L., Chevalier, M., Hervouet, J., Minault, D., Ville, S., Charpy, V., et al. (2014) · mAbs · doi:10.4161/mabs.28375 · Cited by 26 · see citing works

How Biologics Have Changed the Drug Discovery Landscape

McGonigle, P. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080811 · Cited by 26 · see citing works

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab

van Mierlo, G. J. D., Cnubben, N. H. P., Wouters, D., Wolbink, G., Hart, M. H. L., Rispens, T., Ganderup, N., Kuper, C. F., Aarden, L. A., & Penninks, A. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.796023 · Cited by 25 · see citing works

Development of Antibody-Based Therapeutics

Tabrizi, M. A., Klakamp, S. L., & Bornstein, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3 · Cited by 22 · see citing works

The Enhanced Pre- and Postnatal Development Study for Monoclonal Antibodies

Weinbauer, G. F., Luft, J., & Fuchs, A. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-131-8_15 · Cited by 22 · see citing works

Immunotoxicity Testing in Nonhuman Primates

Grote-Wessels, S., Frings, W., Smith, C. A., & Weinbauer, G. F. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-401-2_23 · Cited by 20 · see citing works

The Evolving Landscape of Cancer Therapeutics

Khan, M. M., & Spicer, J. F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_312 · Cited by 18 · see citing works

The Influence of Geographical Origin, Age, Sex, and Animal Husbandry on the Spontaneous Histopathology of Laboratory Cynomolgus Macaques ( Macaca Fascicularis ): A Contemporary Global and Multisite Review of Historical Control Data

Chamanza, R., Naylor, S. W., Gregori, M., Boyle, M., Bacares, M. E. P., Drevon-Gaillot, E., Romeike, A., Courtney, C. L., Johnson, K. A., Turner, J. C., et al. (2022) · Toxicologic Pathology · doi:10.1177/01926233221096424 · Cited by 17 · see citing works

Preclinical Safety Evaluation of Monoclonal Antibodies

Lynch, C. M., & Grewal, I. S. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_2 · Cited by 15 · see citing works

Bioengineering translational models of lymphoid tissues

Michaels, Y. S., Buchanan, C. F., Gjorevski, N., & Moisan, A. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00101-0 · Cited by 15 · see citing works

Muscle wasting associated with pathologic change is a risk factor for the exacerbation of joint swelling in collagen-induced arthritis in cynomolgus monkeys

Horai, N., Nagaoka, T., Higuchi, I., Kasai, H., Yoshioka, T., Umekita, Y., Fukuzaki, K., Nagata, R., Miyata, A., & Abeyama, K. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-205 · Cited by 15 · see citing works

From laboratory to Phase I/II cancer trials with recombinant biotherapeutics

Tolner, B., Smith, L., Hillyer, T., Bhatia, J., Beckett, P., Robson, L., Sharma, S. K., Griffin, N., Vervecken, W., Contreras, R., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.027 · Cited by 14 · see citing works

Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs

Piccotti, J. R., Lebrec, H. N., Evans, E., Herzyk, D. J., Hastings, K. L., Burns‐Naas, L. A., Gourley, I. S., Wierda, D., & Kawabata, T. T. (2009) · Journal of Immunotoxicology · doi:10.1080/15476910802656440 · Cited by 12 · see citing works

Drug Development and Nonclinical to Clinical Translational Databases

Monticello, T. M. (2014) · Toxicologic Pathology · doi:10.1177/0192623314557189 · Cited by 12 · see citing works

Monoclonal Antibodies for Cancer Immunotherapy

Zarnani, A., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_16 · Cited by 11 · see citing works

Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives

Singh, S., Kachhawaha, K., & Singh, S. K. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116303 · Cited by 9 · see citing works

Preclinical evaluation of anti-rheumatic drugs in a non-human primate model of arthritic disease

Vierboom, M., Breedveld, E., & Hart, B. A. ‘. (2008) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2008.06.003 · Cited by 9 · see citing works

Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant Plasmodium falciparum

Zhang, K., Zhao, Y., Zhang, Z., Zhang, M., Wu, X., Bian, H., Zhu, P., & Chen, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.011 · Cited by 7 · see citing works

Primate autoimmune disease models; lost for translation?

Hart, B. A. ‘. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.82 · Cited by 7 · see citing works

Embryo fetal Development Studies in Nonhuman Primates

Fuchs, A., Buse, E., & Weinbauer, G. F. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-131-8_14 · Cited by 6 · see citing works

Formulation development of small and large volume injections

Kamat, M. S., & DeLuca, P. P. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-6 · Cited by 6 · see citing works

Monoclonal Antibodies for Cancer Immunotherapy

Zarnani, A., Jafari, D., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_15 · Cited by 6 · see citing works

The Use of the Marmoset in Toxicity Testing and Nonclinical Safety Assessment Studies

Korte, S., & Everitt, J. I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811829-0.00027-3 · Cited by 6 · see citing works

A novel preclinical model for rheumatoid arthritis research

Petersen, F., & Yu, X. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3181 · Cited by 6 · see citing works

Development of a Sensitive Lateral Flow Immunoassay Using Recombinant Rabbit Single-Chain Variable Fragments Fused to a Nitrocellulose-Binding Protein

Nguyen, N. M., Mukai, R., Nita, M., Yokoyama, F., Nguyen, N.-L. T., Horiuchi, J., & Kumada, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c04510 · Cited by 5 · see citing works

Safety Pharmacology Assessment of Biopharmaceuticals

Amouzadeh, H. R., & Vargas, H. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-25240-2_18 · Cited by 5 · see citing works

Interactions of human IgGs with non-human systems

(2012) · Elsevier eBooks · doi:10.1533/9781908818096.405 · Cited by 4 · see citing works

Opportunities for Implementing the 3 Rs in Drug Development and Safety Assessment Studies Using Nonhuman Primates

Chapman, K. L., Bayne, K. A. L., Couch, J. A., Decelle, T., Finch, J. M., de Haan, L., Koban, T., Mikkelsen, L. F., Müller, W., Palmer, H. S., et al. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00014-7 · Cited by 4 · see citing works

A primate as an animal model for reproductive and developmental toxicity testing

Faqi, A. S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-382032-7.10017-7 · Cited by 3 · see citing works

Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta).

Kumar, B., Kumar, P., Krishna, T. P., Kalyanasundaram, S., Suresh, P., Jagadeesan, V., Hariharan, S., Naidu, A. N., Krishnaswamy, K., Rangarajan, P. N., et al. (2013) · Europe PMC (PubMed Central) · Cited by 3 · see citing works

Developmental and reproductive safety assessment of biopharmaceuticals

Bowman, C., & Martin, P. L. (2016) · CRC Press eBooks · doi:10.3109/9781841848211-21 · Cited by 3 · see citing works

Preclinical Development of Non-Oncogenic Drugs (Small and Large Molecules)

Colerangle, J. B. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00022-8 · Cited by 3 · see citing works

Optimising the Development of Antibodies as Treatment for Cancer

Carden, C. P., Arkenau, H., & Bono, J. S. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_19 · Cited by 3 · see citing works

Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics

de Haan, L. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_10 · Cited by 3 · see citing works

Nonhuman primates as preclinical models for developmental and reproductive toxicity evaluation

Weinbauer, G. F., Fuchs, A., Luetjens, C. M., Niehaus, M., Niehoff, M. O., & Vogelwedde, E. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848211.016 · Cited by 2 · see citing works

Regulations and ethics concerning the use of non-human primates in research

Harvey, W., & Kaiser, R. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-813088-9.00003-3 · Cited by 2 · see citing works

Role of Nonclinical Programs in Drug Development

Srivastava, A. K., & Negi, G. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_35 · Cited by 2 · see citing works

Enhanced pre- and postnatal developmental toxicity (ePPND) study in non-human primates: Necessity, strategic approaches, and critical considerations

Lu, J., Dou, D., Wang, Y., Shu, J., Lei, Z., Huo, Y., & Gong, X. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105814 · Cited by 2 · see citing works

Nonhuman primates as preclinical models for developmental and reproductive toxicity evaluation

Weinbauer, G. F., Fuchs, A., Luetjens, C. M., Niehaus, M., Niehoff, M. O., & Vogelwedde, E. (2016) · CRC Press eBooks · doi:10.3109/9781841848211-20 · Cited by 2 · see citing works

Safety Assessment in Drug Discovery

Sasseville, V. G., Foster, W. R., & Car, B. D. (2009) · doi:10.1002/9780470574898.ch9 · Cited by 2 · see citing works

Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan

Kubota, S., Saito, K., Ono, S., & Kodama, Y. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0160-x · Cited by 1 · see citing works

DRUG DISCOVERY

Vallance, P. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50005-6 · Cited by 1 · see citing works

Biopharmaceutics of NCEs and NBEs

Agoram, B. M., Sagawa, K., Shanker, R., & Singh, S. K. (2012) · CRC Press eBooks · doi:10.3109/9781420086447-4 · Cited by 1 · see citing works

Resolution of unexpected pregnancy‐related findings in a rat embryofetal development and toxicokinetic study of monoclonal antibodies specific for hCMV

Katavolos, P., Prell, R. A., Zane, D., Deng, R., & Halpern, W. (2018) · Birth Defects Research · doi:10.1002/bdr2.1402 · Cited by 1 · see citing works

Biopharmaceuticals as Challenges to the Regulatory System

Ebbers, H. C. (2012) · Utrecht University Repository (Utrecht University) · Cited by 1 · see citing works

Implementation of ICH S 6: EU Perspective

Ryle, P. R., & Snodin, D. J. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse163 · Cited by 1 · see citing works

In vivoMethods for Oral Bioavailability Studies

Ruiz-Garcı́a, A., & Bermejo, M. (2011) · doi:10.1002/9781118067598.ch31 · Cited by 1 · see citing works

Antibody drugs: the present status and perspectives

Kawanishi, T. (2008) · Folia Pharmacologica Japonica · doi:10.1254/fpj.131.102 · Cited by 1 · see citing works

The legal standards for the radioactive or non radioactive drugs research and approval in the European Community and in Germany after the thalidomide catastrophe.

Barsch, M., & Otte, A. (2010) · PubMed · Cited by 1 · see citing works

Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies

Chamberlain, P. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.017 · Cited by 1 · see citing works

References

(2012) · Elsevier eBooks · doi:10.1016/b978-1-907568-37-4.50029-4 · Cited by 1 · see citing works

Preclinical development of monoclonal antibodies

Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 99 · see citing works

Non-human primates in preclinical development of monoclonal antibodies

Макарова, М. Н., & Makarov, V. G. (2023) · Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science) · doi:10.57034/2618723x-2023-02-01

Considerations Regarding Nonhuman Primate Use in Safety Assessment of Biopharmaceuticals

Buckley, L. A., Chapman, K. L., Burns‐Naas, L. A., Todd, M. D., Martin, P. L., & Lansita, J. A. (2011) · International Journal of Toxicology · doi:10.1177/1091581811415875 · Cited by 43 · see citing works

The future of non-human primates in the development of biopharmaceuticals

van Meer, P. J. K., Kooijman, M., van der Laan, J. W., Moors, E. H. M., & Schellekens, H. (2012) · Utrecht University Repository (Utrecht University)

The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies.

Jonker, M. (1990) · PubMed · Cited by 15 · see citing works